Avantor® Reports Third Quarter 2026 Results
• Raised FY 2026 organic revenue growth, adjusted EPS and free cash flow guidance
–Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, reports results that exceeded management’s expectations for revenue and adjusted EPS for the third fiscal quarter of 2026.
Emmanuel Ligner, President and Chief Executive Officer, says: “We are delighted to return to year-over-year growth in the third quarter. We are not done with our Revival journey yet, but this achievement reflects the dedication of our associates and the progress we are making to sharpen our strategic focus and improve execution. Third quarter results exceeded our expectations across revenue and adjusted EPS, and we generated robust free cash flow that allowed us to further strengthen our balance sheet.
“VWR Distribution & Services delivered another quarter of improving revenue performance, with organic growth accelerating to 5.8%, and Bioscience & Medtech Products returned to organic growth as expected. We believe that improving execution and stronger end markets provide a foundation for sustained revenue growth, and we remain focused on execution to build on our positive momentum,” Ligner concludes.
For the three months ended September 30, 2026, net sales were $1,698.3 million, which was up 4.6% compared to the third quarter of 2025. Foreign currency translation had a negative impact of 0.6%, resulting in a 5.2% increase in net sales on an organic basis.
Net income increased to $203.4 million from a net loss of $711.8 million in the third quarter of 2025, and net income margin was 12.0%; adjusted net income was $146.4 million compared to $151.1 million in the prior-year period. Adjusted EBITDA was $256.9 million, with an adjusted EBITDA margin of 15.1%.
Operating income was $139.5 million, with an operating income margin of 8.2%; adjusted operating income was $227.6 million, with an adjusted operating income margin of 13.4%.
Diluted earnings per share on a GAAP basis was $0.30, and adjusted diluted earnings per share was $0.22.
• Net sales were $1,233.8 million, a reported increase of 5.0%, as compared to $1,175.0 million in the third quarter of 2025. Foreign currency translation had a negative impact of 0.8%, resulting in a sales increase of 5.8% on an organic basis.
• Adjusted Operating Income was $119.4 million as compared to $132.0 million in the comparable prior period. Adjusted Operating Income margin was 9.7%. Adjusted Operating Income margin declined versus the prior year due to unfavorable product mix and higher SG&A expenses, partially offset by higher sales volume.
• Net sales were $464.5 million, a reported increase of 3.5%, as compared to $448.8 million in the third quarter of 2025. Foreign currency translation had a negative impact of 0.1%, resulting in a 3.6% sales increase on an organic basis.
• Adjusted Operating Income was $123.4 million, as compared to $119.3 million in the comparable prior period. Adjusted Operating Income margin was 26.6%. Adjusted Operating Income margin was flat versus the prior year due to higher sales volume and commercial excellence, partially offset by higher SG&A expenses.
Adjusted Operating Income is Avantor's segment reporting profitability measure under generally accepted accounting principles and is used by management to measure and evaluate the performance of our Company’s business segments.
As of September 30, 2026, total debt, gross, was $3,699.7 million and cash and cash equivalents were $464.3 million.
GAAP net leverage was 9.6x, and adjusted net leverage was 3.1x, as of September 30, 2026.
For the three months ended September 30, 2026, operating cash flow was $195.1 million, while free cash flow was $156.2 million.
(1) Non-GAAP measure (definitions and/or reconciliations below). We are unable to provide a reconciliation of the non-GAAP measures provided in our full-year 2026 guidance without unreasonable effort because of the difficulty in forecasting and quantifying certain amounts and adjustment items with a reasonable degree of certainty including net income, restructuring charges, foreign currency exchange gains and losses and income tax expense. These amounts are dependent upon future events and may be outside of our control. We note that these items could have a significant impact on our full-year results determined in accordance with GAAP.
• Reported revenue growth range is +1.5% to +2.0%, reflecting +0.75% foreign exchange tailwind
• Net interest expense is expected to decline modestly when compared to Fiscal 2025
We will host a conference call to discuss our results today, October 28, 2026 at 8:00 a.m. Eastern Time. The live webcast and presentation, as well as a replay, will be available on the investor section of Avantor's website .
Avantor ® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit corporate.avantorsciences.com and find us on LinkedIn , X (Twitter) and Facebook .
To evaluate our performance, we monitor a number of key indicators. As appropriate, we supplement our results of operations determined in accordance with U.S. generally accepted accounting principles (“GAAP”) with certain non- GAAP financial measures that we believe are useful to investors, creditors and others in assessing our performance. These measures should not be considered in isolation or as a substitute for reported GAAP results because they may include or exclude certain items as compared to similar GAAP-based measures, and such measures may not be comparable to similarly titled measures reported by other companies. Rather, these measures should be considered as an additional way of viewing aspects of our operations that provide a more complete understanding of our business. We strongly encourage investors to review our consolidated financial statements included in reports filed with the SEC in their entirety and not rely solely on any one single financial measure or communication.
The non-GAAP financial measures used in this press release are sales growth (decline) on an organic basis, Adjusted Operating Income, Adjusted Operating Income margin, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income, adjusted EPS, adjusted net leverage, free cash flow and free cash flow conversion.
• Organic net sales growth (decline) eliminates from our reported net sales change the impacts of revenues from acquisitions and divestitures that occurred in the last year (as applicable) and changes in foreign currency exchange rates. We believe that this measurement is useful to investors as a way to measure and evaluate our underlying commercial operating performance consistently across our segments and the periods presented. This measure is used by our management for the same reason.
• Adjusted Operating Income is our operating income or loss adjusted for the following items: (i) amortization of acquired intangible assets, (ii) charges associated with the impairment of certain assets, (iii) gain or loss on sale of business, and (iv) certain other adjustments. Adjusted Operating Income margin is Adjusted Operating Income divided by net sales as determined under GAAP. We believe that these measures are useful to investors as ways to analyze the underlying trends in our business consistently across the periods presented. These measures are used by our management for the same reason. Additionally, Adjusted Operating Income is our segment reporting profitability measure under GAAP.
• Adjusted EBITDA is our net income or loss adjusted for the following items: (i) interest expense, (ii) income tax expense, (iii) amortization of acquired intangible assets, (iv) depreciation expense, (v) losses on extinguishment of debt, (vi) charges associated with the impairment of certain assets, (vii) gain or loss on sale of business, and (viii) certain other adjustments. Adjusted EBITDA margin is Adjusted EBITDA divided by net sales as determined under GAAP. We believe that these measures are useful to investors as ways to analyze the underlying trends in our business consistently across the periods presented. These measures are used by our management for the same reason.
• Adjusted net income is our net income or loss first adjusted for the following items: (i) amortization of acquired intangible assets, (ii) losses on extinguishment of debt, (iii) charges associated with the impairment of certain assets, (iv) gain or loss on sale of business, and (v) certain other adjustments. From this amount, we then add or subtract an assumed incremental income tax impact on the above-noted pre-tax adjustments, using estimated tax rates, to arrive at Adjusted Net Income. We believe that this measure is useful to investors as a way to analyze the business consistently across the periods presented. This measure is used by our management for the same reason.
• Adjusted EPS is our adjusted net income divided by our diluted GAAP weighted average share count adjusted for anti-dilutive instruments. We believe that this measure is useful to investors as an additional way to analyze the underlying trends in our business consistently across the periods presented. This measure is used by our management for the same reason.
• Adjusted net leverage is equal to our gross debt, reduced by our cash and cash equivalents, divided by our trailing 12-month Adjusted EBITDA (excluding stock- based compensation expense and including the expected run-rate effect of cost synergies and the incremental results of completed acquisitions and divestitures as if those acquisitions and divestitures had occurred on the first day of the trailing 12-month period). We believe that this measure is useful to investors as a way to evaluate and measure the Company’s capital allocation strategies and the underlying trends in the business. This measure is used by our management for the same reason.
• Free cash flow is equal to our cash flows from operating activities, less capital expenditures, plus direct transaction costs and income taxes paid related to acquisitions and divestitures (as applicable) in the period. Free cash flow conversion is free cash flow divided by adjusted net income. We believe that these measures are useful to investors as they provide a view on the Company’s ability to generate cash for use in financing or investing activities. These measures are used by our management for the same reason.
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. These statements may be preceded by, followed by or include the words “aim,” “anticipate,” “assumption,” “believe,” “continue,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “intend,” “likely,” “long-term,” “near-term,” “objective,” “opportunity,” “outlook,” “plan,” “potential,” “project,” “projection,” “prospects,” “seek,” “target,” “trend,” “can,” “could,” “may,” “should,” “would,” “will,” the negatives thereof and other words and terms of similar meaning.
Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in “Risk Factors” in our most recent Annual Report on Form 10-K, and subsequent quarterly reports on Form 10-Q, as such risk factors may be updated from time to time in our periodic filings with the SEC.
All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.
September 30, December 31, (in millions) 2026 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash $ 464.3 $ 365.4 equivalents Accounts 1,122.9 1,074.6 receivable, net Inventory 854.8 818.2 Other current 150.6 193.0 assets Total current 2,592.6 2,451.2 assets Property, plant and equipment, 778.9 766.8 net Other intangible 2,932.3 3,193.8 assets, net Goodwill, net 4,925.9 4,986.9 Other assets 400.3 396.0 Total assets $ 11,630.0 $ 11,794.7 Liabilities and stockholders' equity Current liabilities: Current portion $ 35.0 $ 30.8 of debt Accounts payable 735.4 741.7 Employee-related 174.0 162.7 liabilities Accrued interest 31.5 47.3 Other current 393.1 396.4 liabilities Total current 1,369.0 1,378.9 liabilities Debt, net of 3,648.8 3,915.5 current portion Deferred income 401.9 557.1 tax liabilities Other 374.4 378.2 liabilities Total 5,794.1 6,229.7 liabilities Stockholders’ equity: Common stock including 4,030.5 3,984.8 paid-in capital Treasury stock -75.7 -75.7 at cost Accumulated 1,957.6 1,672.8 earnings Accumulated other -76.5 -16.9 comprehensive loss Total stockholders’ 5,835.9 5,565.0 equity Total liabilities and $ 11,630.0 $ 11,794.7 stockholders' equity
1. Reflects charges incurred during the period related to restructuring initiatives to increase profitability and productivity. Costs included in this caption consist of employee severance, site-exit and contract termination costs, and non-cash impairment charges on long-lived assets associated with site exits.
2. Represents incremental expenses directly associated with the Company’s former cost transformation initiative, which concluded in 2025. These expenses are primarily related to the cost of external advisors.
3. Represents charges and legal costs, net of recoveries, incurred in connection with certain litigation and other contingencies that management evaluates separately from core operating performance.
4. Represents net foreign currency (gain) loss from financing activities, other stock-based compensation expense (benefit) and certain other items that management evaluates separately from core operating performance. The 2025 periods also include a purchase price adjustment related to the 2024 sale of our Clinical Services business and $6.1 million of severance and transition costs associated with the replacement of our Chief Executive Officer.
6. Represents the $785.0 million non-cash goodwill impairment charge recognized in the third quarter of 2025 related to the former Distribution reporting unit.
1. Reflects charges incurred during the period related to restructuring initiatives to increase profitability and productivity. Costs included in this caption consist of employee severance, site-exit and contract termination costs, and non-cash impairment charges on long-lived assets associated with site exits.
2. Represents incremental expenses directly associated with the Company’s former cost transformation initiative, which concluded in 2025. These expenses are primarily related to the cost of external advisors.
3. Represents charges and legal costs, net of recoveries, incurred in connection with certain litigation and other contingencies that management evaluates separately from core operating performance.
4. Represents other stock-based compensation expense (benefit) and certain other items that management evaluates separately from core operating performance. The 2025 periods also include a purchase price adjustment related to the 2024 sale of our Clinical Services business and $6.1 million of severance and transition costs associated with the replacement of our Chief Executive Officer.
5. Represents the $785.0 million non-cash goodwill impairment charge recognized in the third quarter of 2025 related to the former Distribution reporting unit.
(dollars in millions) September 30, 2026 ────────────────────────────────────────────────────────────────────────────── Total debt, gross $ 3,699.7 Less cash and cash equivalents -464.3 $ 3,235.4 Trailing twelve months Adjusted EBITDA $ 982.7 Trailing twelve months ongoing 47.5 stock-based compensation expense $ 1,030.2 Adjusted net leverage (non-GAAP) 3.1 x
Full text with the tables
Exhibit 99.1
Avantor® Reports Third Quarter 2026 Results
• Net sales of $1,698.3 million; increase of 4.6%; organic increase of 5.2%
• Diluted GAAP EPS of $0.30; adjusted EPS of $0.22
• Raised FY 2026 organic revenue growth, adjusted EPS and free cash flow
guidance
RADNOR, Pa. – October 28, 2026
–Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical
products and services to customers in the life sciences and advanced technology
industries, reports results that exceeded management’s expectations for revenue
and adjusted EPS for the third fiscal quarter of 2026.
Emmanuel Ligner, President and Chief Executive Officer, says: “We are delighted
to return to year-over-year growth in the third quarter. We are not done with
our Revival journey yet, but this achievement reflects the dedication of our
associates and the progress we are making to sharpen our strategic focus and
improve execution. Third quarter results exceeded our expectations across
revenue and adjusted EPS, and we generated robust free cash flow that allowed us
to further strengthen our balance sheet.
“VWR Distribution & Services delivered another quarter of improving revenue
performance, with organic growth accelerating to 5.8%, and Bioscience & Medtech
Products returned to organic growth as expected. We believe that improving
execution and stronger end markets provide a foundation for sustained revenue
growth, and we remain focused on execution to build on our positive momentum,”
Ligner concludes.
Third Quarter 2026
For the three months ended September 30, 2026, net sales were $1,698.3 million,
which was up 4.6% compared to the third quarter of 2025. Foreign currency
translation had a negative impact of 0.6%, resulting in a 5.2% increase in net
sales on an organic basis.
Net income increased to $203.4 million from a net loss of $711.8 million in the
third quarter of 2025, and net income margin was 12.0%; adjusted net income was
$146.4 million compared to $151.1 million in the prior-year period. Adjusted
EBITDA was $256.9 million, with an adjusted EBITDA margin of 15.1%.
Operating income was $139.5 million, with an operating income margin of 8.2%;
adjusted operating income was $227.6 million, with an adjusted operating income
margin of 13.4%.
Diluted earnings per share on a GAAP basis was $0.30, and adjusted diluted
earnings per share was $0.22.
Third Quarter 2026 – Segment Results
VWR Distribution & Services
• Net sales were $1,233.8 million, a reported increase of 5.0%, as compared to
$1,175.0 million in the third quarter of 2025. Foreign currency translation had
a negative impact of 0.8%, resulting in a sales increase of 5.8% on an organic
basis.
• Adjusted Operating Income was $119.4 million as compared to $132.0 million in
the comparable prior period. Adjusted Operating Income margin was 9.7%. Adjusted
Operating Income margin declined versus the prior year due to unfavorable
product mix and higher SG&A expenses, partially offset by higher sales volume.
Bioscience & Medtech Products
• Net sales were $464.5 million, a reported increase of 3.5%, as compared to
$448.8 million in the third quarter of 2025. Foreign currency translation had a
negative impact of 0.1%, resulting in a 3.6% sales increase on an organic basis.
• Adjusted Operating Income was $123.4 million, as compared to $119.3 million in
the comparable prior period. Adjusted Operating Income margin was 26.6%.
Adjusted Operating Income margin was flat versus the prior year due to higher
sales volume and commercial excellence, partially offset by higher SG&A
expenses.
Adjusted Operating Income is Avantor's segment reporting profitability measure
under generally accepted accounting principles and is used by management to
measure and evaluate the performance of our Company’s business segments.
Balance Sheet and Cash Flow
As of September 30, 2026, total debt, gross, was $3,699.7 million and cash and
cash equivalents were $464.3 million.
GAAP net leverage was 9.6x, and adjusted net leverage was 3.1x, as of September
30, 2026.
For the three months ended September 30, 2026, operating cash flow was $195.1
million, while free cash flow was $156.2 million.
Updated 2026 Guidance
Avantor updates its fiscal 2026 financial guidance.
Updated Fiscal 2026
Fiscal 2026 guidance guidance
(as of July 29, 2026) (as of October 28, 2026)
──────────────────────────────────────────────────────────────────────────────
Organic revenue -0.5% to +0.5% +0.75% to +1.25%
growth(1)
Adjusted EBITDA 14.8% to 15.3% 14.8% to 15.3%
margin(1)
Adjusted EPS(1) $0.80 to $0.83 $0.81 to $0.83
Free cash flow(1)(2) $500M to $550M $525M to $550M
(1) Non-GAAP measure (definitions and/or reconciliations below). We are unable
to provide a reconciliation of the non-GAAP measures provided in our full-year
2026 guidance without unreasonable effort because of the difficulty in
forecasting and quantifying certain amounts and adjustment items with a
reasonable degree of certainty including net income, restructuring charges,
foreign currency exchange gains and losses and income tax expense. These amounts
are dependent upon future events and may be outside of our control. We note that
these items could have a significant impact on our full-year results determined
in accordance with GAAP.
(2) Excludes cash restructuring costs.
Fiscal 2026 Assumptions
• Reported revenue growth range is +1.5% to +2.0%, reflecting +0.75% foreign
exchange tailwind
• Blended EUR/USD exchange rate of 1.15
• Net interest expense is expected to decline modestly when compared to Fiscal
2025
• Adjusted effective tax rate between 22.0% and 22.5%
• Fully diluted share count of 679M shares
Conference Call
We will host a conference call to discuss our results today, October 28, 2026 at
8:00 a.m. Eastern Time. The live webcast and presentation, as well as a replay,
will be available on the investor section of Avantor's website .
About Avantor
Avantor ® is a leading life science tools company and global provider of
mission-critical products and services to the life sciences and advanced
technology industries. We work side-by-side with customers at every step of the
scientific journey to enable breakthroughs in medicine, healthcare, and
technology. Our portfolio is used in virtually every stage of the most important
research, development and production activities at more than 300,000 customer
locations in 180 countries. For more information, visit
corporate.avantorsciences.com and find us on LinkedIn , X (Twitter) and Facebook
.
Use of Non-GAAP Financial Measures
To evaluate our performance, we monitor a number of key indicators. As
appropriate, we supplement our results of operations determined in accordance
with U.S. generally accepted accounting principles (“GAAP”) with certain non-
GAAP financial measures that we believe are useful to investors, creditors and
others in assessing our performance. These measures should not be considered in
isolation or as a substitute for reported GAAP results because they may include
or exclude certain items as compared to similar GAAP-based measures, and such
measures may not be comparable to similarly titled measures reported by other
companies. Rather, these measures should be considered as an additional way of
viewing aspects of our operations that provide a more complete understanding of
our business. We strongly encourage investors to review our consolidated
financial statements included in reports filed with the SEC in their entirety
and not rely solely on any one single financial measure or communication.
The non-GAAP financial measures used in this press release are sales growth
(decline) on an organic basis, Adjusted Operating Income, Adjusted Operating
Income margin, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income,
adjusted EPS, adjusted net leverage, free cash flow and free cash flow
conversion.
• Organic net sales growth (decline) eliminates from our reported net sales
change the impacts of revenues from acquisitions and divestitures that occurred
in the last year (as applicable) and changes in foreign currency exchange rates.
We believe that this measurement is useful to investors as a way to measure and
evaluate our underlying commercial operating performance consistently across our
segments and the periods presented. This measure is used by our management for
the same reason.
• Adjusted Operating Income is our operating income or loss adjusted for the
following items: (i) amortization of acquired intangible assets, (ii) charges
associated with the impairment of certain assets, (iii) gain or loss on sale of
business, and (iv) certain other adjustments. Adjusted Operating Income margin
is Adjusted Operating Income divided by net sales as determined under GAAP. We
believe that these measures are useful to investors as ways to analyze the
underlying trends in our business consistently across the periods presented.
These measures are used by our management for the same reason. Additionally,
Adjusted Operating Income is our segment reporting profitability measure under
GAAP.
• Adjusted EBITDA is our net income or loss adjusted for the following items:
(i) interest expense, (ii) income tax expense, (iii) amortization of acquired
intangible assets, (iv) depreciation expense, (v) losses on extinguishment of
debt, (vi) charges associated with the impairment of certain assets, (vii) gain
or loss on sale of business, and (viii) certain other adjustments. Adjusted
EBITDA margin is Adjusted EBITDA divided by net sales as determined under GAAP.
We believe that these measures are useful to investors as ways to analyze the
underlying trends in our business consistently across the periods presented.
These measures are used by our management for the same reason.
• Adjusted net income is our net income or loss first adjusted for the following
items: (i) amortization of acquired intangible assets, (ii) losses on
extinguishment of debt, (iii) charges associated with the impairment of certain
assets, (iv) gain or loss on sale of business, and (v) certain other
adjustments. From this amount, we then add or subtract an assumed incremental
income tax impact on the above-noted pre-tax adjustments, using estimated tax
rates, to arrive at Adjusted Net Income. We believe that this measure is useful
to investors as a way to analyze the business consistently across the periods
presented. This measure is used by our management for the same reason.
• Adjusted EPS is our adjusted net income divided by our diluted GAAP weighted
average share count adjusted for anti-dilutive instruments. We believe that this
measure is useful to investors as an additional way to analyze the underlying
trends in our business consistently across the periods presented. This measure
is used by our management for the same reason.
• Adjusted net leverage is equal to our gross debt, reduced by our cash and cash
equivalents, divided by our trailing 12-month Adjusted EBITDA (excluding stock-
based compensation expense and including the expected run-rate effect of cost
synergies and the incremental results of completed acquisitions and divestitures
as if those acquisitions and divestitures had occurred on the first day of the
trailing 12-month period). We believe that this measure is useful to investors
as a way to evaluate and measure the Company’s capital allocation strategies and
the underlying trends in the business. This measure is used by our management
for the same reason.
• Free cash flow is equal to our cash flows from operating activities, less
capital expenditures, plus direct transaction costs and income taxes paid
related to acquisitions and divestitures (as applicable) in the period. Free
cash flow conversion is free cash flow divided by adjusted net income. We
believe that these measures are useful to investors as they provide a view on
the Company’s ability to generate cash for use in financing or investing
activities. These measures are used by our management for the same reason.
Reconciliations of these non-GAAP financial measures to the most directly
comparable GAAP financial measures are included in the tables accompanying this
release.
Forward-Looking and Cautionary Statements
This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, and are subject to the safe harbor created thereby under
the Private Securities Litigation Reform Act of 1995. All statements other than
statements of historical fact included in this press release are forward-looking
statements. Forward-looking statements discuss our current expectations and
projections relating to our financial condition, results of operations, plans,
objectives, future performance and business. These statements may be preceded
by, followed by or include the words “aim,” “anticipate,” “assumption,”
“believe,” “continue,” “estimate,” “expect,” “forecast,” “goal,” “guidance,”
“intend,” “likely,” “long-term,” “near-term,” “objective,” “opportunity,”
“outlook,” “plan,” “potential,” “project,” “projection,” “prospects,” “seek,”
“target,” “trend,” “can,” “could,” “may,” “should,” “would,” “will,” the
negatives thereof and other words and terms of similar meaning.
Forward-looking statements are inherently subject to risks, uncertainties and
assumptions; they are not guarantees of performance. You should not place undue
reliance on these statements. We have based these forward-looking statements on
our current expectations and projections about future events. Although we
believe that our assumptions made in connection with the forward-looking
statements are reasonable, we cannot assure you that the assumptions and
expectations will prove to be correct. Factors that could contribute to these
risks, uncertainties and assumptions include, but are not limited to, the
factors described in “Risk Factors” in our most recent Annual Report on Form
10-K, and subsequent quarterly reports on Form 10-Q, as such risk factors may be
updated from time to time in our periodic filings with the SEC.
All forward-looking statements attributable to us or persons acting on our
behalf are expressly qualified in their entirety by the foregoing cautionary
statements. In addition, all forward-looking statements speak only as of the
date of this press release. We undertake no obligations to update or revise
publicly any forward-looking statements, whether as a result of new information,
future events or otherwise other than as required under the federal securities
laws.
Avantor, Inc. and subsidiaries
Unaudited condensed consolidated statements of operations
(in
mi…
ex… Thr… Nine
per mon… mon…
sh… end… end…
da… Sep… Sep…
20… 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 1,6… $ 1,6… $ 4,9… $ 4,…
sa…
Co…
of 1,1… 1,0… 3,3… 3,…
sa…
Gr… 534… 526… 1,5… 1,…
pr…
Se…
ge…
and 395… 390… 1,2… 1,…
ad…
ex…
Im… — 785… — 78…
ch…
Op…
in… 139… -64… 360… -3…
(l…
In…
ex… -39… -44… -12… -1…
net
Lo…
on
ex… -0.8 -0.2 -2.0 -0…
of
de…
Ot…
(e… -0.8 3.7 -1.9 -1…
in…
net
In…
(l…
be… 98.0 -68… 234… -5…
in…
ta…
In…
tax 105… -22… 50.1 -6…
be…
(e…
Net
in… $ 203… $ -71… $ 284… $ -5…
(l…
Ea…
(l…
per
sh…
Ba… $ 0.30 $ -1.… $ 0.42 $ -0…
Di… $ 0.30 $ -1.… $ 0.42 $ -0…
We…
av…
sh…
ou…
Ba… 677… 681… 676… 68…
Di… 680… 681… 677… 68…
Avantor, Inc. and subsidiaries
Unaudited condensed consolidated balance sheets
September 30, December 31,
(in millions) 2026 2025
──────────────────────────────────────────────────────────────────────────────
Assets
Current assets:
Cash and cash $ 464.3 $ 365.4
equivalents
Accounts 1,122.9 1,074.6
receivable, net
Inventory 854.8 818.2
Other current 150.6 193.0
assets
Total current 2,592.6 2,451.2
assets
Property, plant
and equipment, 778.9 766.8
net
Other intangible 2,932.3 3,193.8
assets, net
Goodwill, net 4,925.9 4,986.9
Other assets 400.3 396.0
Total assets $ 11,630.0 $ 11,794.7
Liabilities and
stockholders'
equity
Current
liabilities:
Current portion $ 35.0 $ 30.8
of debt
Accounts payable 735.4 741.7
Employee-related 174.0 162.7
liabilities
Accrued interest 31.5 47.3
Other current 393.1 396.4
liabilities
Total current 1,369.0 1,378.9
liabilities
Debt, net of 3,648.8 3,915.5
current portion
Deferred income 401.9 557.1
tax liabilities
Other 374.4 378.2
liabilities
Total 5,794.1 6,229.7
liabilities
Stockholders’
equity:
Common stock
including 4,030.5 3,984.8
paid-in capital
Treasury stock -75.7 -75.7
at cost
Accumulated 1,957.6 1,672.8
earnings
Accumulated
other -76.5 -16.9
comprehensive
loss
Total
stockholders’ 5,835.9 5,565.0
equity
Total
liabilities and $ 11,630.0 $ 11,794.7
stockholders'
equity
Avantor, Inc. and subsidiaries
Unaudited condensed consolidated statements of cash flows
(in
mi…
20…
Ca… Thr… Nine
fl… mon… mon…
fr… end… end…
op… Sep… Sep…
ac… 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
in… $ 203… $ -71… $ 284… $ -5…
(l…
Re…
ad…
De…
and 105… 104… 315… 30…
am…
Im… — 785… — 78…
ch…
St…
co… 12.5 7.2 36.5 35…
ex…
No…
re… — — 5.0 —
ch…
Pr…
for
ac… 19.0 16.5 46.2 43…
re…
and
in…
De…
in… -14… -11… -14… -4…
tax
be…
Am…
of
de… 1.8 2.1 5.3 6.6
fi…
co…
Lo…
on
ex… 0.8 0.2 2.0 0.2
of
de…
Fo…
cu…
re… 0.4 -3.1 -0.5 0.7
lo…
(g…
Pe…
te… — — — 18…
ch…
Ch…
in
as…
and
li…
Ac… 12.4 66.2 -68… 10…
re…
In… -44… -33… -90… -6…
Ac… -10… -23… 7.5 -4…
pa…
Ac… -14… -14… -15… -1…
in…
Ot…
as… 54.6 25.5 42.9 -2…
and
li…
Ot… 1.1 -1.3 2.4 1.0
Net
ca…
pr… 195… 207… 432… 47…
by
op…
ac…
Ca…
fl…
fr…
in…
ac…
Ca… -38… -35… -11… -9…
ex…
Ot… 0.4 2.4 1.5 2.5
Net
ca…
us… -38… -33… -10… -9…
in
in…
ac…
Ca…
fl…
fr…
fi…
ac…
De… 54.0 67.7 54.0 67…
bo…
De… -63… -43… -28… -4…
re…
Pr…
re…
fr…
ex… 12.7 2.3 14.6 4.9
of
st…
op…
Sh…
re…
to
sa…
em…
tax -1.1 -0.4 -5.0 -5…
ob…
for
ve…
st…
aw…
Ot… -0.7 — -0.8 —
Net
ca…
pr…
by 1.8 -36… -21… -4…
(u…
in)
fi…
ac…
Ef…
of
cu…
ra…
ch… -0.9 -2.0 -6.8 19…
on
ca…
and
ca…
eq…
Net
ch…
in
ca…
ca… 157… -19… 98.9 -1…
eq…
and
re…
ca…
Ca…
ca…
eq…
and
re… 309… 452… 368… 26…
ca…
be…
of
pe…
Ca…
ca…
eq…
and
re… $ 467… $ 254… $ 467… $ 25…
ca…
end
of
pe…
Avantor, Inc. and subsidiaries
Reconciliations of non-GAAP measures
Adjusted EBITDA and Adjusted EBITDA Margin
… …
──────────────────────────────────────────────────────────────────────────────
$ $
… … … … …
… … … … …
— … — … —
… … … … …
… — — … …
… … … … …
… … … … …
… — — … …
… — — … …
… … … … …
… … … … …
… … … … …
… … … … …
… … … … …
… … … … …
━━━━━━━━━
1. Reflects charges incurred during the period related to restructuring
initiatives to increase profitability and productivity. Costs included in this
caption consist of employee severance, site-exit and contract termination costs,
and non-cash impairment charges on long-lived assets associated with site exits.
2. Represents incremental expenses directly associated with the Company’s former
cost transformation initiative, which concluded in 2025. These expenses are
primarily related to the cost of external advisors.
3. Represents charges and legal costs, net of recoveries, incurred in connection
with certain litigation and other contingencies that management evaluates
separately from core operating performance.
4. Represents net foreign currency (gain) loss from financing activities, other
stock-based compensation expense (benefit) and certain other items that
management evaluates separately from core operating performance. The 2025
periods also include a purchase price adjustment related to the 2024 sale of our
Clinical Services business and $6.1 million of severance and transition costs
associated with the replacement of our Chief Executive Officer.
5. Represents pension termination charges related to termination of our U.S.
Pension Plan.
6. Represents the $785.0 million non-cash goodwill impairment charge recognized
in the third quarter of 2025 related to the former Distribution reporting unit.
Avantor, Inc. and subsidiaries
Reconciliations of non-GAAP measures (continued)
Adjusted Operating Income and Adjusted Operating Income Margin
… …
──────────────────────────────────────────────────────────────────────────────
$ $
… … … … …
… … … … …
… … … … …
— … — … —
… … — … …
… … … … …
… … … … …
… … … … …
… — — … …
… … … … …
… … — … …
… — — … …
… … … … …
━━━━━━━━━
1. Reflects charges incurred during the period related to restructuring
initiatives to increase profitability and productivity. Costs included in this
caption consist of employee severance, site-exit and contract termination costs,
and non-cash impairment charges on long-lived assets associated with site exits.
2. Represents incremental expenses directly associated with the Company’s former
cost transformation initiative, which concluded in 2025. These expenses are
primarily related to the cost of external advisors.
3. Represents charges and legal costs, net of recoveries, incurred in connection
with certain litigation and other contingencies that management evaluates
separately from core operating performance.
4. Represents other stock-based compensation expense (benefit) and certain other
items that management evaluates separately from core operating performance. The
2025 periods also include a purchase price adjustment related to the 2024 sale
of our Clinical Services business and $6.1 million of severance and transition
costs associated with the replacement of our Chief Executive Officer.
5. Represents the $785.0 million non-cash goodwill impairment charge recognized
in the third quarter of 2025 related to the former Distribution reporting unit.
Avantor, Inc. and subsidiaries
Reconciliations of non-GAAP measures (continued)
Adjusted earnings per share
Thr… Nine
(s… mon… mon…
in end… end…
mi… Sep… Sep…
20… 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Di…
ea…
(l… $ 0.30 $ -1.… $ 0.42 $ -0…
per
sh…
(G…
Am… 0.11 0.11 0.34 0.…
Lo…
on
ex… — — — —
of
de…
Re…
se…
and 0.01 — 0.07 0.…
re…
im…
ch…
Tr… — 0.02 — 0.…
ex…
Re…
for
ce… — — 0.01 0.…
le…
ma…
net
Ot… 0.01 0.01 — 0.…
Pe…
te… — — — 0.…
ch…
Im… — 1.15 — 1.…
ch…
In…
tax
be…
ap… -0.… -0.… -0.… -0…
to
pr…
ad…
Ad…
EPS $ 0.22 $ 0.22 $ 0.60 $ 0.…
(n…
We…
av…
di…
sh…
ou…
Sh…
co…
for 680… 681… 677… 68…
Ad…
EPS
(n…
Free cash flow
Thr… Nine
mon… mon…
(in end… end…
mi… Sep… Sep…
20… 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
ca…
pr… $ 195… $ 207… $ 432… $ 47…
by
op…
ac…
Ca… -38… -35… -11… -9…
ex…
Di…
tr…
ex… — — 2.2 1.4
and
ta…
pa…
Fr…
ca… $ 156… $ 171… $ 324… $ 37…
fl…
(n…
GAAP net leverage
(dollars in millions) September 30, 2026
─────────────────────────────────────────────────────────────────────────
Total debt, gross $ 3,699.7
Less cash and cash equivalents -464.3
$ 3,235.4
Trailing twelve months net income $ 337.2
GAAP net leverage 9.6 x
Adjusted net leverage
(dollars in millions) September 30, 2026
──────────────────────────────────────────────────────────────────────────────
Total debt, gross $ 3,699.7
Less cash and cash equivalents -464.3
$ 3,235.4
Trailing twelve months Adjusted EBITDA $ 982.7
Trailing twelve months ongoing 47.5
stock-based compensation expense
$ 1,030.2
Adjusted net leverage (non-GAAP) 3.1 x
Avantor, Inc. and subsidiaries
Reconciliations of non-GAAP measures (continued)
Net sales by segment
Re…
of
net
sa…
gr…
(in (d…
mi… to
Net or… Or…
sa… Fo… net net
gr… cu… sa… sa…
(d… Sep… im… gr… gr…
20… 30, 20… (d… (d…
──────────────────────────────────────────────────────────────────────────────
$ $ $ $ $
Th…
mo…
en…
Bi…
& $ 464… $ 448… $ 15.7 $ -0.6 $ 16…
Me…
Pr…
VWR
Di… 1,2… 1,1… 58.8 -9.0 67…
&
Se…
To… $ 1,6… $ 1,6… $ 74.5 $ -9.6 $ 84…
Ni…
mo…
en…
Bi…
& $ 1,3… $ 1,3… $ -3.4 $ 15.7 $ -1…
Me…
Pr…
VWR
Di… 3,6… 3,5… 86.8 54.7 32…
&
Se…
To… $ 4,9… $ 4,8… $ 83.4 $ 70.4 $ 13…
(…
in Re…
m… of
% net
b… sa…
on gr…
n… (d…
s… to
N… or… O…
s… Fo… net n…
g… cu… sa… s…
(… Se… im… gr… g…
2… 30, 20… (d… (…
──────────────────────────────────────────────────────────────────────────────
$ $ % % %
T…
m…
e…
B…
& $ 46… $ 44… 3.5 % -0… % 3.6 %
M…
P…
V…
D… 1,… 1,… 5.0 % -0… % 5.8 %
&
S…
T… $ 1,… $ 1,… 4.6 % -0… % 5.2 %
N…
m…
e…
B…
& $ 1,… $ 1,… -0… % 1.1 % -1… %
M…
P…
V…
D… 3,… 3,… 2.5 % 1.6 % 0.9 %
&
S…
T… $ 4,… $ 4,… 1.7 % 1.4 % 0.3 %
Adjusted Operating Income by segment
…
…
…
…
… … … …
──────────────────────────────────────────────────────────────────────────────
$ %
$ … … % … … … … … …
… … % … … … … … …
… — % … — … — … —
$ … … % … … … … … …
Investor Relations Contact
Chris Fidyk
Vice President, Investor Relations
Avantor
[email protected]
Global Media Contact
Valerie Collado
Director, External Communications and Community Impact
Avantor
484-885-9338
[email protected]
Source: Avantor and Financial News